Orion Oyj (ORINF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Orion Oyj (ORINF) with AI Score 63/100 (Hold). Orion Oyj is a Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients (APIs). Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Orion Oyj (ORINF) Healthcare & Pipeline Overview
Orion Oyj, a Finnish pharmaceutical company established in 1917, develops and manufactures a diverse portfolio of human and veterinary pharmaceuticals, active pharmaceutical ingredients (APIs), and self-care products, with a global presence and a focus on innovative treatments for various therapeutic areas.
Investment Thesis
Orion Oyj presents a compelling investment case based on its diversified product portfolio, strong market position in select therapeutic areas, and strategic collaborations. The company's focus on developing innovative treatments, particularly in oncology and respiratory diseases, positions it for long-term growth. With a profit margin of 26.5% and a gross margin of 64.2%, Orion demonstrates strong profitability. Key growth catalysts include the continued commercialization of Nubeqa for prostate cancer and the expansion of its Easyhaler product portfolio. Potential risks include regulatory challenges, competition from generic drugs, and the outcome of clinical trials. The company's dividend yield of 2.36% offers an additional incentive for investors.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $11.11 billion reflects Orion Oyj's significant presence in the pharmaceutical industry.
- P/E ratio of 19.55 indicates a reasonable valuation relative to earnings.
- Profit margin of 26.5% demonstrates strong profitability and efficient operations.
- Gross margin of 64.2% highlights the company's ability to generate revenue from its products.
- Dividend yield of 2.36% provides an attractive return for investors.
Competitors & Peers
Strengths
- Diversified product portfolio across human and veterinary pharmaceuticals.
- Strong market position in Finland and Scandinavia.
- Expertise in pharmaceutical development and manufacturing.
- Strategic collaborations with other pharmaceutical companies.
Weaknesses
- Reliance on key products and therapeutic areas.
- Exposure to generic competition.
- Limited presence in some international markets.
- Dependence on collaborations for certain products.
Catalysts
- Ongoing: Continued commercialization of Nubeqa for prostate cancer.
- Ongoing: Expansion of the Easyhaler product portfolio for asthma and COPD.
- Ongoing: Growth in the veterinary drug market.
- Ongoing: Increasing demand for active pharmaceutical ingredients (APIs).
- Upcoming: Potential regulatory approvals for new pharmaceutical products.
Risks
- Potential: Regulatory challenges and pricing pressures in the pharmaceutical industry.
- Ongoing: Competition from generic drugs.
- Potential: Patent expirations on key products.
- Potential: Clinical trial failures for new drug candidates.
- Ongoing: Fluctuations in currency exchange rates.
Growth Opportunities
- Expansion of Nubeqa Sales: Nubeqa, used for the treatment of prostate cancer, represents a significant growth opportunity for Orion. The global prostate cancer market is projected to reach $17.2 billion by 2028, driven by an aging population and increasing awareness of early detection. Orion's collaboration with Bayer for the commercialization of Nubeqa provides access to a wider market and strengthens its position in the oncology space. Continued expansion of Nubeqa sales will be a key driver of revenue growth for Orion.
- Easyhaler Product Portfolio Growth: Orion's Easyhaler product portfolio, used for the treatment of asthma and COPD, offers another avenue for growth. The global asthma and COPD market is expected to reach $45.7 billion by 2027, fueled by increasing air pollution and rising prevalence of respiratory diseases. Orion's focus on developing and marketing innovative Easyhaler products positions it to capture a larger share of this growing market. The company's expertise in inhaled drug delivery and its established distribution network provide a competitive advantage.
- Veterinary Drug Market Expansion: Orion's veterinary drug business presents a growth opportunity driven by the increasing pet ownership and rising demand for animal health products. The global veterinary medicine market is projected to reach $45.7 billion by 2027, driven by increasing pet ownership and rising demand for animal health products. Orion's portfolio of veterinary drugs, including Bonqat, Clevor, and Domosedan, addresses various animal health needs. Expansion into new geographic markets and the development of innovative veterinary products will drive growth in this segment.
- Active Pharmaceutical Ingredients (APIs) Business: Orion's API business offers a growth opportunity driven by the increasing demand for generic drugs and the outsourcing of pharmaceutical manufacturing. The global API market is expected to reach $278.7 billion by 2030, driven by the increasing demand for generic drugs and the outsourcing of pharmaceutical manufacturing. Orion's expertise in API manufacturing and its established relationships with generic drug manufacturers position it to capitalize on this trend. The company's focus on developing and manufacturing high-quality APIs will be a key driver of growth.
- Strategic Collaborations and Licensing Agreements: Orion's strategy of engaging in strategic collaborations and licensing agreements provides access to new technologies and markets. The company's licensing agreement with Tenax Therapeutics for the development of oral levosimendan (TNX-103) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF) demonstrates its commitment to innovation. Continued pursuit of strategic collaborations and licensing agreements will be crucial for expanding Orion's product portfolio and entering new therapeutic areas.
Opportunities
- Expansion into new geographic markets.
- Development of innovative pharmaceutical products.
- Acquisition of complementary businesses.
- Increased demand for veterinary drugs.
Threats
- Regulatory changes and pricing pressures.
- Competition from generic drugs.
- Patent expirations.
- Clinical trial failures.
Competitive Advantages
- Strong brand reputation and established market presence in Finland and Scandinavia.
- Diversified product portfolio across various therapeutic areas.
- Expertise in pharmaceutical development, manufacturing, and marketing.
- Strategic collaborations and licensing agreements with other pharmaceutical companies.
About ORINF
Founded in 1917 and headquartered in Espoo, Finland, Orion Oyj has evolved into a prominent pharmaceutical company with a global reach. The company develops, manufactures, and markets a wide range of human and veterinary pharmaceuticals, active pharmaceutical ingredients (APIs), and self-care products. Orion's pharmaceutical product portfolio includes treatments for various therapeutic areas, such as oncology (Nubeqa for prostate cancer), Parkinson's disease (Entacapone, Stalevo, Comtess, Comtan), inflammatory pain (Burana), menopausal symptoms (Divina series), acute decompensated heart failure (Simdax), breast cancer (Fareston), antipsychotic conditions (Quetiapine products), rheumatoid arthritis and cancer (Trexan), asthma and COPD (Easyhaler product portfolio), and sedation (Dexdor, Precedex, Dexmedetomidine products). In addition to human pharmaceuticals, Orion offers a range of veterinary drugs, including Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie. The company also manufactures APIs for generic compounds and proprietary products, provides contract manufacturing services, and markets and sells drugs and products manufactured by other companies. Furthermore, Orion offers self-care products, including non-prescription medicines, cosmetics, dietary supplements, vitamins, and skincare products. The company distributes its products through various channels, including online sales.
What They Do
- Develops and manufactures human pharmaceuticals for various therapeutic areas.
- Offers veterinary drugs for animal health.
- Produces active pharmaceutical ingredients (APIs) for generic and proprietary products.
- Provides contract manufacturing services to other pharmaceutical companies.
- Markets and sells drugs and products manufactured by other companies.
- Offers self-care products, including non-prescription medicines, cosmetics, and dietary supplements.
- Sells products online.
Business Model
- Develops and manufactures pharmaceutical products.
- Generates revenue through sales of human and veterinary pharmaceuticals, APIs, and self-care products.
- Enters into licensing agreements and collaborations to develop and commercialize new products.
- Provides contract manufacturing services to other pharmaceutical companies.
Industry Context
Orion Oyj operates in the global pharmaceutical industry, which is characterized by intense competition, stringent regulatory requirements, and rapid technological advancements. The industry is driven by factors such as an aging population, increasing prevalence of chronic diseases, and growing demand for innovative treatments. Orion competes with other major pharmaceutical companies, including BDUUY (Bayer), BIOVF (BioDelivery Sciences International), CHJTF (Chiesi Farmaceutici), CSPCY (CSPC Pharmaceutical Group), and ERFSF (Eren Pharmaceuticals Holding). The company's focus on niche therapeutic areas and strategic collaborations helps it to differentiate itself in the competitive landscape.
Key Customers
- Patients who use human pharmaceuticals.
- Veterinarians and pet owners who use veterinary drugs.
- Pharmaceutical companies that purchase APIs.
- Consumers who purchase self-care products.
Financials
Chart & Info
Orion Oyj (ORINF) stock price: Price data unavailable
Latest News
No recent news available for ORINF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ORINF.
Price Targets
Wall Street price target analysis for ORINF.
MoonshotScore
What does this score mean?
The MoonshotScore rates ORINF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
ORINF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Orion Oyj may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more challenging for investors to assess their financial health and performance compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Lower liquidity and wider bid-ask spreads.
- Increased price volatility.
- Potential for fraud or manipulation.
- Higher risk of delisting or going out of business.
- Verify the company's registration and regulatory filings.
- Review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the company's management team and track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any news or regulatory actions related to the company.
- Established history as a pharmaceutical company since 1917.
- Diversified product portfolio across human and veterinary pharmaceuticals.
- Strategic collaborations with reputable pharmaceutical companies like Bayer.
- Global presence and operations in multiple countries.
- Dividend yield of 2.36%.
ORINF Healthcare Stock FAQ
What does Orion Oyj do?
Orion Oyj is a Finnish pharmaceutical company that develops, manufactures, and markets a wide range of human and veterinary pharmaceuticals, active pharmaceutical ingredients (APIs), and self-care products. The company's human pharmaceutical products include treatments for various therapeutic areas, such as oncology, Parkinson's disease, inflammatory pain, and respiratory diseases. Orion also offers a range of veterinary drugs for animal health. In addition, the company manufactures APIs for generic compounds and proprietary products, provides contract manufacturing services, and markets and sells drugs and products manufactured by other companies. Orion distributes its products globally, with a significant presence in Scandinavia and Europe.
What do analysts say about ORINF stock?
As of March 15, 2026, a comprehensive analyst consensus for ORINF is pending AI analysis. Investors should monitor financial news sources for updated analyst ratings and price targets. Key valuation metrics to consider include the company's P/E ratio of 19.55, profit margin of 26.5%, and dividend yield of 2.36%. Growth considerations include the continued commercialization of Nubeqa, expansion of the Easyhaler product portfolio, and growth in the veterinary drug market. Investors should conduct their own due diligence and consider their individual investment objectives before making any investment decisions.
What are the main risks for ORINF?
Orion Oyj faces several risks inherent to the pharmaceutical industry. These include regulatory challenges and pricing pressures, competition from generic drugs, patent expirations on key products, and the potential for clinical trial failures for new drug candidates. As an OTC-traded stock, ORINF also faces risks related to limited financial disclosure, lower liquidity, and increased price volatility. Additionally, fluctuations in currency exchange rates can impact the company's financial performance, given its global operations. Investors should carefully consider these risks before investing in ORINF.
What are the key factors to evaluate for ORINF?
Orion Oyj (ORINF) currently holds an AI score of 63/100, indicating moderate score. Key strength: Diversified product portfolio across human and veterinary pharmaceuticals.. Primary risk to monitor: Potential: Regulatory challenges and pricing pressures in the pharmaceutical industry.. This is not financial advice.
How frequently does ORINF data refresh on this page?
ORINF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ORINF's recent stock price performance?
Recent price movement in Orion Oyj (ORINF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diversified product portfolio across human and veterinary pharmaceuticals.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ORINF overvalued or undervalued right now?
Determining whether Orion Oyj (ORINF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ORINF?
Before investing in Orion Oyj (ORINF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for ORINF, which may provide further insights.
- OTC market investments carry additional risks.